Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Efruxifermin by Akero Therapeutics for Type 2 Diabetes: Likelihood of Approval
Efruxifermin is under clinical development by Akero Therapeutics and currently in Phase II for Type 2 Diabetes. According to GlobalData,...
Efruxifermin by Akero Therapeutics for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Likelihood of Approval
Efruxifermin is under clinical development by Akero Therapeutics and currently in Phase III for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)....
Efruxifermin by Akero Therapeutics for Liver Cirrhosis: Likelihood of Approval
Efruxifermin is under clinical development by Akero Therapeutics and currently in Phase III for Liver Cirrhosis. According to GlobalData, Phase...
Efruxifermin by Akero Therapeutics for Metabolic Dysfunction-Associated Steatohepatitis (MASH): Likelihood of Approval
Efruxifermin is under clinical development by Akero Therapeutics and currently in Phase III for Metabolic Dysfunction-Associated Steatohepatitis (MASH). According to...
Risk adjusted net present value: What is the current valuation of Akero Therapeutics's Efruxifermin?
Efruxifermin is a fusion protein commercialized by Akero Therapeutics, with a leading Phase III program in Metabolic Dysfunction-Associated Steatohepatitis (MASH)....